BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–
small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF …

Opinion Statement BRAF mutations are present in up to 8% of human cancers, and
comprise a viable therapeutic target in many patients harboring these mutations. Specific …

The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …

Highlights•BRAF alterations lead to unbridled activation of the MAPK pathway which can
result in cancer development and progression.•BRAF and MEK inhibitors led to paradigm …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

3517 Background: BRAF V600 mutations occur in 5-15% of metastatic CRC and predict
poor prognosis. Although highly effective in BRAF mutant melanoma, BRAF inhibitor …

BRAF V600 mutations occur in a wide range of tumor types, and RAF inhibition has become
standard in several of these cancers. Despite this progress, BRAF V600 mutations have …

Discussion Activating mutations in BRAF codon 600 are central drivers in aberrant
constitutive mitogen-activated protein kinase (MAPK) activity and have been identified in …

Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in
approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …